{"id":60531,"date":"2026-03-23T14:28:57","date_gmt":"2026-03-23T06:28:57","guid":{"rendered":"https:\/\/flcube.com\/?p=60531"},"modified":"2026-03-23T14:28:58","modified_gmt":"2026-03-23T06:28:58","slug":"china-nhc-issues-medical-technology-evaluation-procedures-new-framework-triggers-restrictions-or-bans-on-controversial-clinical-practices","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60531","title":{"rendered":"China NHC Issues Medical Technology Evaluation Procedures \u2013 New Framework Triggers Restrictions or Bans on Controversial Clinical Practices"},"content":{"rendered":"\n

China’s National Health Commission (NHC)<\/strong> issued the “Work Procedures for Evaluating the Clinical Application of Medical Technologies”<\/strong>, establishing a comprehensive regulatory framework<\/strong> for assessing medical technologies already in clinical use \u2013 with provisions to ban, restrict, or strengthen management<\/strong> of procedures facing safety controversies, adverse events, or ethical concerns.<\/p>\n\n\n\n

Regulatory Framework Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Issuing Agency<\/strong><\/td>National Health Commission (NHC)<\/td><\/tr>
Document<\/strong><\/td>Work Procedures for Evaluating the Clinical Application of Medical Technologies<\/td><\/tr>
Scope<\/strong><\/td>Medical technologies already in clinical use (exclusions noted below)<\/td><\/tr>
Organizing Body<\/strong><\/td>NHC Medical Administration Center<\/td><\/tr>
Technical Support<\/strong><\/td>National quality control centers, national medical centers, industry associations<\/td><\/tr>
Evaluation Dimensions<\/strong><\/td>Safety, efficacy, ethical risks<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Evaluation Trigger Conditions<\/h2>\n\n\n\n
Trigger Category<\/th>Specific Circumstances<\/th><\/tr><\/thead>
1. Industry Controversy<\/strong><\/td>Significant professional disagreement regarding clinical application<\/td><\/tr>
2. Safety Incidents<\/strong><\/td>Major\/multiple adverse events (non\u2011operational); uncontrollable risks<\/td><\/tr>
3. Scientific Advances<\/strong><\/td>New understanding of safety\/efficacy due to technological progress<\/td><\/tr>
4. Evidence\u2011Based Concerns<\/strong><\/td>New domestic\/international evidence of quality\/safety issues; international phase\u2011out or prohibition<\/td><\/tr>
5. Institutional Reporting<\/strong><\/td>Uncertain effects or significant quality\/safety\/ethical risks reported by provincial health departments, NHC affiliates, medical centers, quality control centers, or industry associations<\/td><\/tr>
6. Regulatory Monitoring<\/strong><\/td>Serious abnormalities identified during oversight activities<\/td><\/tr>
7. Public Attention<\/strong><\/td>Concentrated public complaints or high social attention<\/td><\/tr>
8. Other Circumstances<\/strong><\/td>Additional scenarios requiring evaluation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Evaluation Outcomes & Management Measures<\/h2>\n\n\n\n
Conclusion Category<\/th>Management Action<\/th>Application Scope<\/th><\/tr><\/thead>
1. Ban<\/strong><\/td>Prohibition from clinical use<\/strong><\/td>Uncertain safety\/efficacy; significant ethical issues; clinically obsolete; internationally prohibited<\/td><\/tr>
2. Restricted Technology Catalog<\/strong><\/td>Strict management by provincial+ health authorities<\/strong><\/td>High technical difficulty; high risk; high professional standards required; scarce resource consumption; major ethical risks; irrational clinical application requiring focused management<\/td><\/tr>
3. Enhanced Management<\/strong><\/td>Strengthened oversight through revised norms, procedures, and quality control<\/td>Technologies not reaching ban\/restriction thresholds but requiring improved clinical application management<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Scope Exclusions<\/h2>\n\n\n\n

The Work Procedures do not apply<\/strong> to:<\/p>\n\n\n\n